CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

Roberto, Michela and Astone, Antonio and Botticelli, Andrea and Carbognin, Luisa and Cassano, Alessandra and D’Auria, Giuliana and Fabbri, Agnese and Fabi, Alessandra and Gamucci, Teresa and Krasniqi, Eriseld and Minelli, Mauro and Orlandi, Armando and Pantano, Francesco and Paris, Ida and Pizzuti, Laura and Portarena, Ilaria and Salesi, Nello and Scagnoli, Simone and Scavina, Paola and Tonini, Giuseppe and Vici, Patrizia and Marchetti, Paolo (2021) CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers, 13 (2). p. 332. ISSN 2072-6694

[thumbnail of cancers-13-00332.pdf] Text
cancers-13-00332.pdf - Published Version

Download (1MB)

Abstract

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype, and endocrine therapy (ET) remains its therapeutic backbone. Although anti-estrogen therapies are usually effective initially, approximately 50% of HR+ patients develop resistance to ET within their lifetime, ultimately leading to disease recurrence and limited clinical benefit. The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to ET have remarkably improved the outcome of patients with HR+ advanced breast cancer (ABC) compared with anti-estrogens alone, by targeting the cell-cycle machinery and overcoming some aspects of endocrine resistance. However, which patients are the better candidates for these drugs, which are the main characteristics for a better selection of patients or if there are predictive biomarkers of response, is still unknown. In this review we reported the mechanism of action of CDK4/6 inhibitors as well as their potential mechanism of resistance, their implications in clinical practice and the forthcoming strategies to enhance their efficacy in improving survival and quality of life of patients affected with HR+, HER2−, ABC.

Item Type: Article
Subjects: Journal Eprints > Medical Science
Depositing User: Managing Editor
Date Deposited: 22 Dec 2022 12:47
Last Modified: 31 May 2024 09:36
URI: http://repository.journal4submission.com/id/eprint/518

Actions (login required)

View Item
View Item